Assurex Health Launches JV with Canadian Mental Health Center | GenomeWeb

NEW YORK (GenomeWeb News) – Assurex Health has created a public-private partnership with Canada's Centre for Addiction and Mental Health (CAMH) to offer the firm's pharmacogenomic test to help guide psychiatric treatments, the company said yesterday.

Assurex Health and CAMH have launched the joint venture AssureRx Canada to provide the GeneSight test, which measures and analyzes genomic variants to help physicians select the appropriate treatments for depression, anxiety, bipolar disorder, schizophrenia, and other neuropsychiatric conditions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.